Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

Fig. 3

CircEAF2 counteracts the progression of EBV + DLBCL in vitro. A CircEAF2 overexpression in Farage cells and circEAF2 silencing in SU-DHL-4 cells. B CCK8 assay evaluated cell proliferation at each time point. C and D Annexin V-APC apoptosis (C) and TUNEL assay (D) detected lymphoma cell apoptosis (ratio). E Dose-response curves and the half maximal inhibitory concentration (IC50) for epirubicin on circEAF2-overexpressing cells or circEAF2-slienced cells. Scale bar represented 200 μm. Si-NC, Negative control siRNA; Si-circEAF2, circEAF2 siRNA; TUNEL, Terminal dexynucleotidyl transferase (TdT)-mediated dUTP nick end labeling; DAPI, 4′,6-diamidino-2-phenylindole; IC50, Half maximal inhibitory concentration. Data were shown as the mean ± S.D. of three experiments

Back to article page

Molecular Cancer

ISSN: 1476-4598